Pharmaceutical industry exposure in our hospitals: the final frontier
MetadataShow full item record
The relationship between the medical profession and the pharmaceutical industry has changed considerably over the last two decades. While the days of expenses-paid overseas conferences and golf trips may be over, pharmaceutical company presence is still felt not only in private practice but also in our hospitals. Some of these interactions benefit patients; in particular, industry-sponsored clinical trials and research studies in hospitals. Besides generating new evidence and drugs, patients who participate in clinical trials in hospitals appear to have better outcomes and lower mortality.1 However, there is a risk that industry sponsorship may unduly influence clinician researchers or the hospital itself. To reduce (but not eliminate) this risk, hospitals must comply with mandatory national research governance frameworks through the implementation of local policies and procedures, and researcher codes of conduct, overseen by research ethics committees.2
Medical Journal of Australia
Dean J, Loh E and Coleman JJ. Pharmaceutical industry exposure in our hospitals: the final frontier. Med J Aust 2016; 204 (1): 20-22. © Copyright 2016 The Medical Journal of Australia – reproduced with permission.
Public Health and Health Services not elsewhere classified